Axs-05
Agitation,Psychomotor
Axsome Therapeutics, Inc.unclassifiedPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Agitation,Psychomotor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 4 | A |
Wellbutrin Axsome Therapeutics, Inc. | Phase 2/3 | B |
Igc Ad1 IGC Pharma, LLC | Phase 2 | CCC |
Low THC Mclean Hospital | Early Phase 1 | C |
Marijuana M. H MediCane Ltd. | N/A | D |
Loxapine Wake Forest University Health Sciences | D |
Same molecule, other indications
Axs-05 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →